A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-05. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
== Mechanism == The enzyme uses pyridoxal phosphate (PLP), the active form of vitamin B6, as a cofactor. PLP is essential to the mechanism of decarboxylation in AADC. In the active enzyme, PLP is bound to lysine-303 of AADC as a Schiff base. Upon substrate binding, Lys-303 is displaced by the substrate's amine. This positions the carboxylate of the substrate within the active site such that decarboxylation is favored. Decarboxylation of the substrate produces a quinonoid intermediate, which is subsequently protonated to produce a Schiff base adduct of PLP and the decarboxylated product. Lys-303 can then regenerate the original Schiff base, releasing the product while retaining PLP. Probing this PLP-catalyzed decarboxylation, it has been discovered that there is a difference in concentration and pH dependence between substrates. DOPA is optimally decarboxylated at pH 6.7 and a PLP concentration of 0.125 mM, while the conditions for optimal 5-HTP decarboxylation were found to be pH 8.3 and 0.3 mM PLP.
Task Force 1-41 Infantry was a US Army heavy battalion task force from the 2nd Armored Division (Forward). 2nd Armored Division (Forward) included the 1st Battalion, 41st Infantry Regiment, the 2nd and 3rd Battalions, 66th Armor Regiment, and the 4th Battalion, 3rd Field Artillery Regiment. Task Force 1–41 was the first coalition force to breach the Saudi Arabian border on 15 February 1991, and to conduct ground combat operations in Iraq against the enemy on 17 February 1991. Shortly after arrival in theatre "..the battalion received, for planning, a brigade cross-boundary counter-reconnaissance mission." 1–41 Infantry was assisted by the 1st Squadron, 4th Armored Cavalry Regiment. This joint effort would become known as Task Force Iron. Counter-reconnaissance generally includes destroying or repelling the enemy's reconnaissance elements and denying their commander any observation of friendly forces. On 15 February 1991 4th Battalion of the 3rd Field Artillery Regiment fired on a trailer and a few trucks in the Iraqi sector observing American forces. On 16 February 1991 several groups of Iraqi vehicles appeared to be performing reconnaissance on the Task Force and were driven away by fire from 4–3 FA. Another enemy platoon, including six vehicles, was reported as being to the northeast of the Task Force. They were engaged with artillery fire from 4–3 FA. Later that evening another group of Iraqi vehicles was spotted moving towards the center of the Task Force. They appeared to be Iraqi Soviet-made BTRs and tanks.
== Enzyme-Linked Single Molecule Array (eSimoa) == eSimoa (enzyme-linked single molecule array) represents a significant evolution of the traditional ELISA (Enzyme-Linked Immunosorbent Assay) technique, which is widely utilized in clinical diagnostics and research. By significantly enhancing the sensitivity and resolution of biomolecular detection, eSimoa expands the capabilities of ELISA, enabling the detection of biomolecules at concentrations previously unachievable with standard assays.
Sources: en.wikipedia.org
=== Other === Some light hydrocarbons are used as aerosol sprays. Alkanes from hexadecane upwards form the most important components of fuel oil and lubricating oil. In the latter function, they work at the same time as anti-corrosive agents, as their hydrophobic nature means that water cannot reach the metal surface. Many solid alkanes find use as paraffin wax, for example, in candles. This should not be confused however with true wax, which consists primarily of esters. Alkanes with a chain length of approximately 35 or more carbon atoms are found in bitumen, used, for example, in road surfacing. However, the higher alkanes have little value and are usually split into lower alkanes by cracking.
For comparison with lower dosages, the suppression of circulating testosterone levels in men with a dosage of 100 mg/day oral CPA was 77% and with a dosage of 300 mg/week intramuscular CPA was 76%. Dosages of CPA of 12.5 to 25 mg/day have been used as a maintenance dosage for testosterone suppression in men with sexual deviance after initial administration of higher CPA dosages, without recurrence of symptoms. CPA is generally able to maximally suppress circulating testosterone levels by 70 to 80% in men. However, in spite of strong suppression of testosterone levels, CPA, at least by itself (e.g., without estrogen), is not usually able to reduce testosterone levels into the castrate/female range (<50 ng/dL) at any dosage, and testosterone levels generally remain just above it at levels of roughly 50 to 200 ng/dL. However, studies have reported that a very high dosage of CPA of 300 mg/day may suppress testosterone levels to around 50 ng/dL in men. CPA also suppresses estradiol levels in men, with one study finding about a 65% decrease in estradiol levels (from about 27 pg/mL to around 10 pg/mL) with 100 mg/day CPA. CPA has been found to maximally suppress testosterone and estradiol levels in young men within 7 days of continuous administration. Following discontinuation of CPA, the recovery of testosterone levels is variable and may require 14 days to 6 months for completion. An escape or recovery phenomenon, in which testosterone levels increase over time, has been observed with long-term CPA monotherapy.
=== Silage === Lactiplantibacillus plantarum is the most common bacterium used in silage inoculants. During the anaerobic conditions of ensilage, these organisms quickly dominate the microbial population, and, within 48 hours, they begin to produce lactic and acetic acids via the Embden-Meyerhof Pathway, further diminishing their competition. Under these conditions, L. plantarum strains producing high levels of heterologous proteins have been found to remain highly competitive. This quality could allow this species to be utilized as an effective biological pretreatment for lignocellulosic biomass.
== Promotions == Runza is a vendor in Memorial Stadium, home of the Nebraska Cornhuskers football team, In 2017, the Omaha Storm Chasers, Omaha's Triple-A affiliate of the Kansas City Royals Major League Baseball team, rebranded themselves as the "Omaha Runzas" in a cross-promotional event. The team's rebranded uniforms featured a cartoon runza sandwich and shared the green and yellow livery of the Runza restaurant chain. Runza operated a 1950s themed Rock n' Roll Runza featuring memorabilia, vintage automobiles and roller skating carhops out of downtown Lincoln from 1991 to 2004.
Sources: en.wikipedia.org
By the second half of the 20th century, several large-scale industrial processes had been developed in which nitriles were either produced or utilized. An important example is the development of polyamides (polyamide 6.6) in the 1930s, as adiponitrile is a key intermediate in its manufacture and is produced by hydrocyanation of butadiene with hydrogen cyanide. Acrylonitrile polymers have been known since the 1920s but gained greater importance as synthetic fibers toward the late 1940s. Superglues based on cyanoacrylates have also been available since the late 1940s.
Absorption bases, e.g., beeswax and wool fat Emulsifying bases, e.g., cetrimide and emulsifying wax Hydrocarbon bases, e.g., ceresine, microcrystalline wax, hard paraffin, and soft paraffin Vegetable oil bases, e.g., almond oil, coconut oil, olive oil, peanut oil, and sesame oil Water-soluble bases, e.g., macrogols 200, 300, 400 The water number of an ointment is the maximum quantity of water that 100g of a base can contain at 20 °C. Ointments are formulated using hydrophobic, hydrophilic, or water-emulsifying bases to provide preparations that are immiscible, miscible, or emulsifiable with skin secretions. They can also be derived from hydrocarbon (fatty), absorption, water-removable, or water-soluble bases. Evaluation of ointments:
== System software == Honeywell provided up to 500 software packages that could run on the H-316 processor. A FORTRAN IV compiler was available, as well as an assembler, real-time disk operating systems and system utilities and libraries.
Next, an epimerization domain changes the stereochemistry of L-alanine (L-Ala) into D-alanine (D-Ala). CesB is a 305 kDa heterodimer protein composed of CesB1 and CesB2 modules. CesB1 behaves almost identically to CesA1, where ketoisocaproic acid was added and reduced; however, the substrate α-ketoisovaleric acid is reduced to L- α-hydroxyisovaleric acid (L-HIV). Additionally, a condensation domain at the end of CesA (beyond CesA2) facilitates the ester formation between L-HIV and the D-HIC-D-Ala peptide. Next, CesB2 adds L-valine (L-Val) to the adenylation domain, and the condensation domain facilitates the nucleophilic attack of the amine on L-Val onto the D-HIC-D-Ala-L-HIV thioester, which creates a D-HIC-D-Ala-L-HIV-L-Val tetrapeptide on the thiolation domain of CesB2. Finally, the final thioesterase domain combines three units of the aforementioned tetrapeptide between the α-hydroxyl group of D-HIC and the thioester of a L-Val of another tetrapeptide. Ultimately, three esters are formed during this cyclization of 3 tetrapeptides. The resulting cyclic depsipeptide, which contains alternating units of esters and amides, is cereulide.
=== Tropoelastin precursors === Elastin is made by linking together many small soluble precursor tropoelastin protein molecules (50-70 kDa), to make the final massive, insoluble, durable complex. The unlinked tropoelastin molecules are not normally available in the cell, since they become crosslinked into elastin fibres immediately after their synthesis by the cell and export into the extracellular matrix. Each tropoelastin consists of a string of 36 small domains, each weighing about 2 kDa in a random coil conformation. The protein consists of alternating hydrophobic and hydrophilic domains, which are encoded by separate exons, so that the domain structure of tropoelastin reflects the exon organization of the gene. The hydrophilic domains contain Lys-Ala (KA) and Lys-Pro (KP) motifs that are involved in crosslinking during the formation of mature elastin. In the KA domains, lysine residues occur as pairs or triplets separated by two or three alanine residues (e.g. AAAKAAKAA) whereas in KP domains the lysine residues are separated mainly by proline residues (e.g. KPLKP). The hydrophobic domains of tropoelastin are enriched in non-polar amino acids, particularly glycine, valine, proline, and alanine, whereas its lysine-rich domains provide sites for enzymatic cross-linking during the formation of mature elastin.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.